ENTPD1 and neoplasm: In a previous study, CD39+CD73+ tumor cells reduced the proliferation of CD4+ T and CD8+ T cells by CD39 and the adenosine dependent pathway, and treatment with CD39 inhibitors or blocking antibodies reduced the tumor-induced inhibition (41).